iRadimed Corporation (NASDAQ:IRMD - Get Free Report) Director Monty Allen sold 1,419 shares of the firm's stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total transaction of $122,615.79. Following the transaction, the director owned 19,581 shares in the company, valued at $1,691,994.21. This represents a 6.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
iRadimed Price Performance
Shares of NASDAQ:IRMD opened at $84.40 on Wednesday. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of 47.15 and a beta of 0.89. iRadimed Corporation has a 12 month low of $67.84 and a 12 month high of $107.90. The stock's 50 day moving average price is $91.77 and its 200 day moving average price is $93.37.
iRadimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.The firm had revenue of $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, sell-side analysts expect that iRadimed Corporation will post 1.98 EPS for the current year.
iRadimed Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were paid a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed's dividend payout ratio (DPR) is currently 44.69%.
Institutional Investors Weigh In On iRadimed
Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada boosted its stake in shares of iRadimed by 14.7% during the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider's stock worth $1,354,000 after acquiring an additional 3,307 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of iRadimed by 7.5% in the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider's stock worth $831,000 after acquiring an additional 1,108 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock worth $252,000 after purchasing an additional 234 shares during the period. Jones Financial Companies Lllp raised its position in shares of iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider's stock worth $591,000 after purchasing an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of iRadimed by 1.1% during the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock valued at $8,889,000 after purchasing an additional 1,821 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have commented on the stock. Weiss Ratings cut shares of iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, August 3rd. Wall Street Zen lowered shares of iRadimed from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, iRadimed presently has a consensus rating of "Moderate Buy" and a consensus target price of $120.00.
Get Our Latest Stock Report on IRMD
iRadimed Company Profile
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
